30 June 2021
The 6th World Psoriasis and Psoriatic Arthritis Conference (WPPAC) 2021 opens in a novel virtual format and features the latest groundbreaking developments in the field of psoriasis and psoriatic arthritis research. The conference includes plenaries, lectures, oral presentation of abstracts on the latest research, presentations of challenging cases, and interactive sessions featuring Key Opinion Leaders from all over the world. The WPPAC is a unique cross-specialty forum and explores perspectives from dermatology, rheumatology, and more, all within the context of topics and priorities from people living with psoriatic disease.
With the unique challenges posed by the ongoing COVID pandemic, the 6th WPPAC 2021 is transformed for the first time into a fully virtual meeting. This new format facilitates participation from everyone in our community around the world, regardless of national travel restrictions.
The theme of the 6th WPPAC 2021 is Connected, informed, and united to improve multidisciplinary care for people with psoriasis & psoriatic arthritis. The program features topics of interest to everyone active within the fields of psoriasis and psoriatic arthritis – clinicians as well as researchers. The patient perspective is centered throughout the conference, underscored by the presence and participation of patient experts and leaders.
Join Conference President Professor Ulrich Mrowietz and IFPA President Dr. Hoseah Waweru as they open the conference and discuss what to look forward to.
Professor Kenji Kabashima from Japan speaks and answers questions about new pathways/drivers of immunity.
Dr Rachel Summer from Germany speaks and answers questions about patient reported outcomes. The focus of her lecture is on measuring wellbeing – not only burden of disease.
Plenary and interactive Q&A sessions
There are 3 plenary sessions on Wednesday, June 30, each followed by a live Q&A with the speakers
This plenary session on pathogenesis features lectures and live Q&A with Professor Johan Gudjonsson and Professor Vinod Chandran who focuses on the pathogenesis of psoriasis and psoriatic arthritis, respectively.
This plenary session is about treatment guidelines and includes a lectures on treatment guidelines/best practices for psoriasis from Professor Alexander Nast and for psoriatic arthritis from Professor Arthur Kavanaugh. The session also ends with a live Q&A with the speakers.
Day 1’s final plenary session is all about new treatments and provides updates on new treatments/pipeline from Professor Kristian Reich for psoriasis and Professor Philip Mease for psoriatic arthritis.
The Complementary Program is primarily directed at allied health professionals, non-specialists, patient leaders, and industry representatives. It is broken up into two sessions on Day 1: the first focuses on the global burden of psoriasis/psoriatic arthritis and the second on the intersection between COVID-19 and psoriatic disease.
13:00-14:00 CEST: Global burden of psoriasis/psoriatic arthritis
This session opens the Complementary Program and includes an introduction and talk about the global burden of disease from Professor Chris Griffiths, an update on the Global Psoriasis Atlas from Professor Darren Ashcroft, and a talk on improving access to care from Professor Luca Borradori. The lectures are followed by an interactive Q&A.
16:00-17:00 CEST: Psoriatic disease and COVID-19
The hot topic this year of COVID-19 and psoriatic disease is broached by a presentation on psoriasis and COVID-19 by Dr. Satveer Mahil and Professor Catherine Smith from PsoProtect, insights on how COVID-19 affects the care of patient from Professor Peter van de Kerkhof, and a talk on vaccination against SARS-CoV-2 in people with psoriatic disease from Conference President Professor Ulrich Mrowietz. The session is followed up with a live Q&A.
Oral abstract presentations
Day 1 features findings from two major abstracts:
Effisayil 1: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of spesolimab in patients with a generalized pustular psoriasis presented by Professor Mark Lebwohl
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results From the Phase presented by Professor April Armstrong
Poster abstracts are available online from Wednesday, June 30. Don’t forget to stop by the virtual abstract hall to learn about the very latest research on psoriasis and psoriatic arthritis.
Join us tomorrow for Day 2!
Theme: “Connected, informed, and united to improve multidisciplinary care for people with psoriasis & psoriatic arthritis”
Dates: June 30 – July 3, 2021
Venue: Virtual Conference broadcast from Stockholm, Sweden
Target group: Dermatologists, rheumatologists and general practitioners and allied health professionals with an interest in psoriasis and psoriatic arthritis
Twitter: @PsoriasisIFPA, #WPPAC21
Camille Lancelot, IFPA Communications Manager.
Telephone: +46 73 961 15 65
Sign up to our newsletter